Table 6 Cost effectiveness of drug eluting versus bare metal stents (baseline) after 12 months of follow up.

		Elective surgery risk groups				Non‐elective surgery risk groups
		A	B	C	D	X	Y	Z
Incremental cost per QALY gained
Stent	No used
Sirolimus	1	£144900	£71500	£0*	−£24000*	£68500	−£25400*	−£54100*
	2	£363400	£216500	£73600	£25600	£226000	£38300	−£19100*
	3	£582000	£361600	£147200	£75200	£383500	£102000	£15800*
	Mean	£238900	£179700	£85200	£51600	£133600	£30600	−£23700*
Paclitaxel	1	£205800	£113000	£22700	−£7700*	£113500	£5100*	−£41400*
	2	£481900	£296300	£115700	£55000	£312500	£75400	£2800*
	3	£758100	£479600	£208700	£117700	£511600	£155800	£46900
	Mean	£324400	£249700	£130200	£87900	£195800	£65700	−£3000*
Maximum price premium per drug eluting stent
Stent	ICER
Sirolimus	£30000	£170	£209	£330	£416	£271	£497	£888
	£0	£122	£150	£238	£300	£205	£376	£671
Paclitaxel	£30000	£134	£164	£259	£325	£213	£388	£683
	£0	£96	£118	£186	£234	£161	£293	£517

*Cost effective scenario.

ICER, incremental cost effectiveness ratio.

£1 ˜ US$1.8/[euro ]1.4.